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During recent years increasing attention has been devoted to long-
term toxicity and quality of life of patients treated for testicular
cancer (Moynihan, 1987; Roth et al, 1988; Aass et al, 1990; Bissett
et al, 1990), fertility being an important dimension of psychosocial
well-being and post-treatment morbidity.
Spermatogenesis is often transiently inhibited by modern stan-
dard chemotherapy (Drasga et al, 1983; Berthelsen, 1984; Brenner
et al, 1985; Lange et al, 1987) with gradual recovery 10–18 months
after discontinuation of chemotherapy. After retroperitoneal lymph
node dissection (RPLND), ‘dry ejaculation’ represents a major risk
of infertility, especially if this operation has to be done in patients
with extended retroperitoneal metastases (Hermanek and Sigel,
1982; Wood et al, 1982; Lange et al, 1984; Fosså et al, 1991). Post-
RPLND dry ejaculation is due to the resection of sympathetic nerves
entering the superior hypogastric plexus (Jewett et al, 1988). After
the original bilateral template RPLND almost all patients suffered
from post-operative dry ejaculation, even if done as modified
RPLND thus sparing the contralateral iliac region below the iliac
bifurcation (Whitmore, 1982). Early in the 1980s unilateral template
RPLND was developed (Fosså et al, 1984a; Pizzocaro et al, 1985;
Weissbach et al, 1985). After this operation antegrade ejaculation
remained in 80% of the patients. During the mid 1980s Donohue
et al (1990) introduced nerve-sparing RPLND in the treatment of
testicular cancer patients.
Unilateral and nerve-sparing RPLND techniques were primarily
developed for patients with no or limited retroperitoneal tumour
manifestations and were mostly applied as diagnostic means in
testicular cancer patients without preceding chemotherapy. During
the 1980s it became evident that more limited techniques of
RPLND, such as unilateral (Fosså et al, 1985a) or nerve-sparing
(Jewett et al, 1988) RPLND, might be sufficient. Some institutions
even used unilateral RPLND techniques as post-chemotherapy
surgical procedures. Other institutions performed resection of
residual macroscopic tumours rather than a formal RPLND
(Hendry et al, 1993).
In the present paper we summarize the Norwegian Radium
Hospital’s (NRH) experience with post-chemotherapy RPLND
from 1980 to 1994. The aim was to investigate the impact of
different types of RPLND on ejaculatory function and thus on
fertility.
MATERIALS AND METHODS
Patients
From 1980 to 1994 about 400 patients with testicular cancer
underwent RPLND at the NRH, Oslo. A total of 192 operations
were performed after cisplatin-based induction chemotherapy in
patients presenting with metastases. Survival data are given for
these 192 patients. The analysis of ejaculatory function and
fertility comprises 174 men, excluding 13 patients who had died at
the time of investigation (March 1996) and for whom the medical
records did not contain any information about post-RPLND ejacu-
lation (Table 1). Also excluded were four patients with severe
psychological disturbances from whom no valid information could
be obtained as regards ejaculatory function and one patient who
was lost to follow-up without any information on ejaculatory func-
tion and fertility in his medical record. The patients’ initial staging
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Summary The purpose of this study was to evaluate fertility after different types of post-chemotherapy retroperitoneal lymph node dissection
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limited residual retroperitoneal masses after induction chemotherapy can safely undergo limited post-chemotherapy RPLND as a part of
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based on clinical examination, thoraco-abdominal computerized
tomography (CT) and measurements of serum choriogonadotropin
(HCG) and alpha fetoprotein (AFP).
Treatment principles
Cisplatin-based induction chemotherapy was given to all patients
with ³IIB non-seminomatous testicular cancer o r  ³IIC semi-
noma. Post-chemotherapy RPLND was to be done 4–10 weeks
after induction chemotherapy in non-progressing patients who
had initially presented with retroperitoneal tumour masses, even
though these had completely regressed after cytostatic treatment as
evidenced by abdominal CT (Fosså et al, 198 5a). Until about
1985 patients with advanced seminoma were included in post-
chemotherapy RPLND treatment, but this policy was gradually
abandoned thereafter (Fosså et al, 1987, 1988).
Chemotherapy
From 1978 and the early 1980s, induction chemotherapy consisted
of 4–6 cycles with the PVB regimen (cisplatin, vinblastine,
bleomycin) (Narayan et al, 1982; Fosså et al, 1988; Aass et al,
1991). A few patients from 1980 to 1981 also received adriamycin
as a component of consolidation treatment. From 1985, vinblastine
was gradually substituted by VP-16 (bleomycin, etoposide,
cisplatin [BEP]). From 1988, patients were included in interna-
tional randomized trials evaluating the e ffect of carboplatin and
ifosfamide in patients with germ cell tumours (Loehre r , 1990;
Bajorin et al, 1993; Bosl and Motze r , 1997).
Surgical procedures for RPLND
Three types of RPLND were carried out during the 15-year period
(Table 2).
Modified bilateral template RPLND
This operation was routine from 1980 to 1984 and followed the
recommendations of Whitmore (1979): excluding the great
vessels, all retroperitoneal soft tissue was excised as an anatomical
template.
Unilateral template RPLND
From 1985 to 1988, resection of retroperitoneal tissue was
confined to the ipsilateral side of the aortic midline in patients with
retroperitoneal tumour disease confined to one template.
During nerve-sparing RPLND the sympathetic nerve fibres
were carefully dissected out, identified and preserved, at least on
one side (Donohue et al, 1990). Unilateral template nerve-sparing
RPLND (Figure 1) was introduced in 1992 by one of the authors
(SO) for patients with tumours confined to the ipsilateral template.
V ia a midline abdominal incision the peritoneum was incised
from the foramen of  Winslo w, distally around the caecum and
proximall y, along the left side of the mesenteric root, to the supe-
rior mesenteric arter y. The right colon and the mesentery of the
small intestine were sharply mobilized o ff the thin fascia covering
the retroperitoneal compartment and placed on the patient ’ s chest.
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Table 1Demographics
No. of patients
Total 174
1980–1984  33
1985–1988  61
1989–1994  80
Age (years)  27 1
(15–57)2
Side of the tumour
Right 78
Left  96
Prior testicular maldescent
Y es 1 7
No  140
Unknown  17
Histology
TD  13
MTI 66
MTU 75
MTT 15
Seminoma  5
Stage (at start of induction chemotherapy)
II 92
III 18
IV  64
Maximum diameter of retroperitoneal mass (mm)
Before chemotherapy  46 (10–150)
After chemotherapy  22 (0–120)
No. of cycles induction chemoth.
1–2  2
36
4  134
5–6  25
> 6  7
Observation period (months)  52 1 (10–198)2
Relapse (overall)  17
Retroperitoneal relapse  4
1Median; 2(range). TD = teratoma di f ferentiated (teratoma); MTI = malignant
teratoma intermediate (teratocarcinoma); MTU = malignant teratoma
undif ferentiated (embryonal carcinoma); MTT = malignant teratoma
trophoblastic (choriocarcinoma).
Table 2Y ear of retroperitoneal surgery and type of RPLND (A), stage (B)
and size of retroperitoneal mass (C) (192 patients)
Year of surgery
1980–19841985–19881989–1994 Total
631 42 87 192
A.  Type of RPLND
Bilateral template  58 1 (92%)  27 (64%)  14 (16%)  99
Unilateral template  3  1 1  17  31
Nerve-sparing  2  4  56  62
B.  Tumour stage
II 22 (35%)  24 (57%)  54 (62%)  100
III 5  5  8  18
IV  36  13  25  74
C. Largest diameter (mm)
Pre-chemotherapy  31 2 35  30  46
(15–150)3 (17– 1 15)  (10–136)  (10–150)
Post-chemotherapy  13  14  16  22
(0–120)  (0–87)  (0– 1 10)  (0–120)
1Number of patients; 2median; 3(range).The pancreas and the third part of duodenum were mobilized. With
the left-sided template, the inferior mesenteric artery was routinely
divided near to the aorta and the mesentery of the sigmoid
colon was mobilized. The inferior mesenteric vein was usually
preserved.
The nerve-sparing dissection commenced with the visual identi-
fication of the hypogastric nerves on the anterior surface of the
aortic bifurcation, beneath the thin subperitoneal fascia covering
aorta and the retroperitoneal compartment. The nerve bundles
were safeguarded with a rubberband and followed proximally,
until they diverged to their sides of origin. The landmark was
usually identifiable at a ganglion at the pre-aortic level just distal
to the origin of the inferior mesenteric artery. This ganglion was
preserved. The nerve trunks belonging to the template of the
ipsilateral template were removed. No further attempt was
performed to dissect tissues on the opposite side.
Starting at the common iliac artery the tissue covering the great
vessels was ligated, divided, mobilized and rolled off the circum-
ference of the vessels proceeding stepwise proximally along the
anterior midline of the vessels. Lumbal vessels were visualized,
secured and divided. Following complete mobilization of the great
vessels from the posterior abdominal wall within the appropriate
template, all soft tissue was removed from the retroperitoneal
space and the anterior spinous ligament. The root of the mesentery
was repositioned and the peritoneum covering the posterior
abdominal wall repaired with interrupted sutures.
Post-RPLND management
No further treatment was given in patients with complete post-
chemotherapy resections if the histology revealed complete
necrosis/fibrosis or mature teratoma. Patients with viable cancer
tissue in the resection specimen received three cycles of post-
operative adjuvant chemotherapy (Hollender et al, 1997).
Follow-up
All patients were seen at the NRH’s outpatient department or at a
local hospital with 2–6 months’ intervals during the first 3–5
years, with no subsequent follow-up visits at the NRH. In all
patients, a post-operative abdominal CT was performed about 2
months after RPLND. Routine follow-up investigations comprised
clinical examination, measurements of serum HCG, AFP and
regular chest X-rays. CT examinations were only performed when
clinically indicated.
Assessment of spermatogenesis and fertility
Before 1985 only those patients were assessed for pre-treatment
fertility who spontaneously expressed plans for post-treatment
paternity and in whom pre-treatment semen cryopreservation was
considered. From 1985, information of testicular maldescent,
previous fatherhood and involuntary infertility was routinely
obtained. Evaluation of fertility was routinely done in all patients
at the time of the initial referral to the NRH (2–3 weeks after
unilateral orchiectomy, which usually was performed at the
patient’s local hospital). The serum hormone levels of luteinizing
hormone (LH), follicle-stimulating hormone (FSH) and testos-
terone were measured. Light microscopic sperm cell analysis in
the post-masturbation seminal fluid obtained after 3 days’ sexual
abstinence was done assessing sperm cell density (´ 106 ml–1),
mobility (grade 1–4) and motility (% mobile sperm cells). For the
sake of simplification only sperm cell density will be considered in
the present study. Whenever possible, serum hormone analyses
and sperm analysis were repeated 1 and 3 years after discontinua-
tion of all treatment. In addition, at the follow-up visits patients
were to be asked about their post-operative ejaculatory function,
their partners’ eventual pregnancies and about involuntary infer-
tility. If indicated, couples with infertility problems were referred
to the University Infertility Clinic of the National Hospital, Oslo.
For the purpose of the study, a questionnaire was mailed to 165
living patients in March 1996 asking them for more recent infor-
mation about post-treatment fatherhood, infertility and ejaculatory
function. The patients were asked to categorize their ejaculation as
‘normal’ (antegrade), ‘varying’ (sometimes antegrade, sometimes
‘dry ejaculation’), or as ‘dry ejaculation’ (never seminal fluid per
urethram). The completed form, which represented the principal
source of this study’s outcome parameters, was returned by 155
patients (94%). For the ten patients who did not respond to the
mailed questionnaire, and for nine patients who had died by the
time of investigation, comparable information from the medical
record was considered in the analysis.
Statistical analysis
The data were analysed by the PC-version 6.0 of the SPSS using
standard statistics (median, mean, range, c2 test, Student’s t-test).
Due to the small number of paired results from sperm counts we
decided to analyse all available pre- and post-treatment samples as
independent parameters. Cancer-specific survival was assessed by
the Kaplan–Meier method, evaluating differences between curves
by the log-rank test. A P-value < 0.05 was regarded as statistically
significant.
RESULTS
Performance of RPLND
During 1980–1984, 58 of 63 RPLNDs (92%) were performed
as bilateral template operations (Table 2). This percentage had
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Figure 1 Schematic presentation of the unilateral nerve-sparing RPLND.
The pre-aortic sympathetic ganglion close to the origin of the inferior
mesenteric artery is attempted to be preserved together with the hypogastric
nerve bundledecreased to 16% (14 of 87) during the third period. This reduction
was not related to less advanced retroperitoneal tumour masses in
the third period, though the percentage of stage II patients had
increased gradually (Table 2B and C).
Relapse and survival
In 30 of the 192 patients, the malignancy relapsed after RPLND.
In 26 of these patients, residual viable cancer was found in the
operation specimen; residual mature teratoma was demonstrated
in four patients. In seven of these 26, recurrent retroperitoneal
tumour masses were found at the time of relapse. Three of the
seven patients had undergone modified bilateral template RPLND,
one had had unilateral template RPLND and three patients were
operated on by a nerve-sparing technique. The recurrent retro-
peritoneal tumours were resected in four patients, the histology
showing viable malignant tumour tissue in one of them. In the
three remaining patients with retroperitoneal relapse, all of them
after nerve-sparing RPLND, the histology of the recurrent tumour
was ‘mature teratoma’. The former patient subsequently died of
the germ cell malignancy, whereas the three other patients remain
tumour-free. With a median observation time of 96 months (range
27–205) for surviving patients the cancer-specific survival was not
significantly correlated with the period of RPLND (Figure 2).
Antegrade ejaculation was at least partially preserved in 17 of
the 61 (28%) patients operated on during the first 5 years as
compared to two of 33 patients (8%) and 63 of 80 patients (79%)
in the second and third period respectively (Table 3).
Sixty-seven of 89 patients (75%) complained of dry ejaculation
after bilateral modified template RPLND (Table 4). The compa-
rable figures after nerve-sparing operations were three of 56 (5%).
Dry ejaculation occurred in six of 29 patients (21%) operated on
by unilateral template RPLND, three of them operated due to
right-sided and three operated for left-sided tumours.
The median ejaculatory volume decreased from 4.4 ml before
RPLND (64 patients) to 2.5 ml after the operation (26 patients)
(P < 0.001, Table 5). With the reservation of small numbers, the
reduction of the ejaculatory volume was least after nerve-sparing
RPLND as compared to the template RPLND techniques without
nerve-sparing. The sperm cell density remained unchanged.
Fifty-six of the 157 evaluable patients (36%) attempted to achieve
fatherhood after their treatment (Table 6). Of the 35 patients with
antegrade/variable ejaculation 18 were successful, two of them by
fertilization using the patient’s post-treatment sperm cells. Only nine
of the 21 patients with dry ejaculation who planned paternity
achieved fatherhood after their treatment, seven patients by assisted
fertilization using the pre-treatment sperm cells from the sperm bank,
and two patients after treatment with sympathomimetic agents.
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Figure 2 Cancer-specific survival in patients with metastatic testicular cancer undergoing post-chemotherapy RPLND at the NRH (- – – –) 1980–1984, (——)
1985–1988, (. . . .) 1989–1994
Table 3 Ejaculation and years for RPLND
Year of surgery
Ejaculation 1980–1984 1985–1988 1989–1994 Total
Antegrade 17 (28%) 2 (6%) 63 (79%) 82
Variable 5 (8%) 5 (15%) 6 (7%) 16
‘Dry’ 39 (64%) 26 (79%) 11 (14%) 76
Total 61 33 80 174
Table 4 Ejaculation and type of RPLND
Type of surgery
Ejaculation Modified bilateral Unilateral Nerve-sparing Total
template template
Antegrade 10 (11%) 22 (76%) 50 (89%) 82
Variable 12 (13%) 1 (3%) 3 (5%) 16
‘Dry’ 67 (75%) 6 (21%) 3 (5%) 76
Total 89 29 56 174DISCUSSION
In a prospective study from Norway (Aass and Fosså, 1988) 67%
of the patients, at the time of diagnosis of testicular cancer, stated
that they definitely planned to have children after their treatment,
especially the younger non-seminoma patients.
Several investigators have shown the time-dependent recovery
of spermatogenesis in 60–80% of the patients treated with
platin-based chemotherapy (Fosså et al, 1985b; Lampe et al,
1997). The preservation of patients’ ejaculatory function thus
becomes a major issue for maintenance of fertility. Furthermore,
for many men, the experience of antegrade ejaculation represents
an important component of an undisturbed sexual life. The present
paper therefore predominantly deals with ejaculatory function 1
year or later after RPLND, assessed by the volume of the ejaculate.
Secondarily, we also evaluated the sperm count, though these
results are dependent more on the type of chemotherapy than of
RPLND. Contrary to ejaculatory function, sperm cell density also
improves with time after the first post-treatment year.
Post-chemotherapy RPLND continues to be an important
approach in the management of testicular cancer in Norway even
in patients with a normal abdominal CT. The necrotic/fibrotic
tissue may include microscopic foci of mature teratoma (Fosså
et al, 1984b, 1992). The general belief is that complete resection of
this histological subtype is essential for long-time progression-free
survival. Foci of vital malignant germ cell tumour may also be
found (Fosså et al, 1992).
Initial RPLND techniques focused on complete removal of all
lymphatic tissue. Loss of emission and antegrade ejaculation, and
thus infertility, were the main late side-effects after post-
chemotherapy bilateral template RPLND as performed in the early
1980s. With a better understanding of the pattern of the lymphatic
spread of testicular cancer more limited RPLND techniques have
been developed. The preservation of the hypogastric plexus and
the inferior mesenteric ganglion is of particular importance for the
maintenance of antegrade ejaculation and preservation of neural
continuity of at least one side saves antegrade ejaculation.
Antegrade ejaculation is thus preserved in 80% of the patients
after unilateral template RPLND more often after right-sided than
left-sided RPLND (Lange et al, 1984; Fosså et al, 1984a, 1985a,
1988).
Nerve-sparing RPLND was initially introduced as an alternative
technique for primary surgical staging of low-stage non-semi-
noma. Donohue et al (1990) attempted to identify the sympathetic
fibres emerging from the thoraco-lumbal ganglia on both sides and
to preserve their continuity by thorough dissection of the retroperi-
toneal lymphatic tissue surrounding the nerves. At least 90% of
patients operated on with this technique preserved antegrade
ejaculation. Subsequently, the above technique was also applied
during post-chemotherapy RPLND in patients with limited
residual retroperitoneal masses (Donohue et al, 1990). This
accounts to about two-thirds of the patients requiring RPLND after
induction chemotherapy.
The technique used at the NRH after 1992 represents a modifi-
cation of Donohue et al’s original technique and is attempted only
if limited tumour masses are confined to one side. Emphasis is put
on the preservation of the hypogastric plexus and the inferior
mesenteric ganglion together with the preservation of neuro-
continuity of the sympathetic fibres on the non-tumour-bearing
side. This is achieved by omission of any resection of the
contralateral side’s lymphatic tissue. The lymphatic tissue on the
tumour-bearing side is removed with a subsequent template resec-
tion proximally to the inferior mesenteric ganglion. In experienced
hands the complete operation usually takes 2–3 h. Only in extra-
ordinary cases, with very limited residual tumour masses on both
sides, is resection of the lymphatic tissue on both sides performed.
Identification and preservation of the bilateral sympathetic fibres
is in these cases attempted, thus following the original recommen-
dations for nerve-sparing technique (Donohue et al, 1990).
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Table 5 Sperm analysis
RLND type Pre-treatment Post-treatment P-value
Bilateral template
24 patients 5 patients
Volume (ml) 3.91 (1.0–9.7)2 2.3 (1.7–4.0) 0.04
Density (´ 106 ml-1) 14 (0–75) 12.5 (0–35) NS
Unilateral template
10 patients 6 patients
Volume (ml) 5.7 (1.4–11.3) 2.6 (0.7–5.3) 0.03
Density (´ 106 ml-1) 27.5 (2–61) 17.5 (1–99) NS
Nerve-sparing
30 patients 15 patients
Volume (ml) 3.3 (0.5–6.3) 2.8 (0.9–6.6) 0.03
Density (´ 106 ml-1) 16.5 (0–143) 38 (0–869) NS
All
64 patients 26 patients
Volume (ml) 4.4 (0.5–11.3) 2.5 (0.7–6.6) < 0.0013
Density (´ 106 ml-1) 16.5 (0–76) 25.0 (0–99) NS
1Median; 2range; 3Wilcoxon rank test.
Table 6 Fertility and ejaculatory function
Antegrade/variable ‘Dry ejaculation’
(98 patients) (76 patients)
Age at orchiectomy (years) 27 ± 81 27 ± 9
Prior testicular maldescent 12 5
Observation time (months) 77 ± 41 133 ± 46
No. of cycles
< 4 4 4
47 4 6 0
> 4 20 12
No. of children before orchiectomy
06 0 3 8
11 1 1 2
21 2 1 3
> 2 7 4
Unknown 8 9
FSH after treatment (U l-1) 15.4 ± 11 17.7 ± 14
Attempted fatherhood
after treatment/evaluable 35/90 21/67
Achieved paternity (³ ´ 1) 18 (2)2 9 (7)3 (2)4
No. of paternities after
treatment
11 4 9 5
23
61
No. of patients with
attempts of assisted
fertilization 2 10
1Mean ± standard deviation; 2,3,4Number of paternities achieved by assisted
fertilization with fresh2 or frozen3 semen or after sympathomimetic agents4;
5Twins in two cases and triplets in one patient.The policy of performing nerve-sparing post-chemotherapy
RPLND, whenever possible, has been followed by antegrade or
variable ejaculation in 86% of the patients operated from 1989 to
1994, and antegrade ejaculation is preserved in 95% of the patients
by nerve-sparing technique. However, the seminal fluid volume
decreases as compared to the pre-treatment situation. The fact that
with a median observation time of 55 months about one-third of
the patients have attempted fatherhood underlines the clinical
importance of preservation of antegrade ejaculation. An additional
advantage of preserved antegrade ejaculation is that the patients’
post-treatment semen may be used for assisted fertilization if
fatherhood can not be achieved by ‘natural means’.
Hendry et al (1992) had similar favourable results as concerns
preservation of antegrade ejaculation when removing a residual
mass rather than performing a formal RPLND. No data are so far
available which would indicate the superiority of either treatment.
At present we recommend institutions to choose the type of opera-
tion they feel most confident with.
After post-chemotherapy nerve-sparing RPLND there might
be slightly increased risk of a retroperitoneal recurrence. Safe
follow-up of these patients is essential and requires the close coop-
eration between clinicians and radiologists. The interpretation of
post-RPLND abdominal CTs requires thorough knowledge of the
typical visualization of the post-operative anatomy. The perfor-
mance of unilateral template RPLND, but in particular of nerve-
sparing RPLND, requires experience in the technical aspects of the
operation, understanding of the tumour biology of advanced testic-
ular cancer after induction chemotherapy and a close cooperation
with the responsible oncologist and pathologist. Only major
cancer centres will probably gain sufficient experience which lead
to optimal results.
The present report leads to the following conclusions:
1. Modern treatment of chemotherapy of testicular cancer has to
take into account that at least one-third of the patients want to
father a child after their treatment.
2. Post-chemotherapy RPLND can safely be done by nerve-
sparing techniques in most patients with limited residual
retroperitoneal tumour masses.
3. Nerve-sparing post-chemotherapy RPLND preserves ante-
grade ejaculation in about 90% of the patients and enables
post-treatment paternity in at least 50% of those who attempt
fatherhood after their treatment.
4. The close cooperation between oncologists, surgeons, patholo-
gists and radiologists is a condition sine qua non in the
fertility-preserving approach nerve-sparing RPLND.
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